Common hotspots of cancer chemotherapy

被引:0
作者
Adekunle Fiyin Ademikanra
Olutayo Micheal Oyewole
Azeemat Olanrewaju Olayiwola
机构
[1] San Diego State University,Department of Biology
[2] Ladoke Akintola University of Technology,Department of Biochemistry
[3] Federal University Oye-Ekiti,Department of Microbiology
关键词
Cancer; Carcinogenesis; Carcinoma; Sarcoma; Blastoma; Lymphoma; Leukemia; Oncogenes; Chemotherapy;
D O I
10.1007/s42764-023-00101-9
中图分类号
学科分类号
摘要
Cancer is fundamentally a disturbance in the regulation of tissue development. Normal cells must undergo alterations in the genes responsible for cell proliferation and differentiation for cancer to arise. Carcinogenesis is the process through which cancer originates in healthy cells. It is characterized by cellular, genetic, and epigenetic alterations, as well as abnormal cell division. Oncogenes may be either normal genes with aberrant expression or mutant genes with surprising new abilities. Cancers are categorized with respect to the cell type involved in the cancerous growth. The categories include Carcinoma (Epithelial cells: lungs, breast, prostate, pancreas, intestine), Sarcoma (connective tissues: bone, cartilage, fat, nerves), Lymphoma & Leukaemia (immune system: lymph node & blood), Blastoma (embryonic cells), Germ cell tumour (ovarian & testicular germ cell). Cancer diagnosis involve an array of medical examinations such as blood count and X-ray imaging using electron endoscopy and computer-generated tomography. Tissue diagnosis reflects the histological grade, genetic abnormalities, and other properties of the proliferating cells which aid physicians in selecting the optimal course of treatment and determining the patient's prognosis. Cancer exhibits no visible symptoms except general symptoms such as unintended weight loss and fatigue. Chemotherapy refers to the use of one or more cytotoxic antineoplastic drugs (chemotherapeutic agents) in a specified treatment regime. It targets rapidly dividing cells, and its effectiveness is dependent on the type and severity of the disease. Classes of chemotherapeutic drugs are Alkylating agents, antimetabolites, Antitumor antibiotics, hormonal agents, plants alkaloids and miscellaneous agents. Other treatment of cancer includes the use of radiation, laser therapy, immunotherapy, and surgery. Cancer hotspots are areas of tumour DNA that are more susceptible to alteration. Examples of oncogenes with cancer hotspots include BRCA genes, p53 genes, APC genes, HER genes, PALB2 genes, ATM genes, ALK genes etc.
引用
收藏
页码:181 / 196
页数:15
相关论文
共 511 条
[1]  
Aas T(1996)Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients Nature Medicine. 2 811-814
[2]  
Børresen AL(2018)Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: Temporal phases of Li–Fraumeni syndrome Current Opinion in Oncology. 30 23-29
[3]  
Geisler S(2004)Multicenter international study of oxaliplatin/5-fluorouracil/leukovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators: Oxaliplatin, fluorouracil and leukovorin as adjuvant treatment for colon cancer New England Journal of Medicine 50 2243-2251
[4]  
Smith-Sørensen B(2014)Breast-cancer risk in families with mutations in PALB2 New England Journal of Medicine. 371 497-506
[5]  
Johnsen H(2016)Radiation therapy for breast cancer: Literature review Medical Dosimetry. 41 253-257
[6]  
Varhaug JE(1998)Functional interaction of an axin homolog, conductin, with β-catenin, APC, and GSK3β Science 280 596-599
[7]  
Amadou A(2007)A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 395-402
[8]  
Waddington Achatz MI(2018)DNA and chromosome damage induced by bleomycin in mammalian cells: An update Mutation Research/reviews in Mutation Research. 775 51-62
[9]  
Hainaut P(2003)Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: Are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Annals of Oncology. 14 406-413
[10]  
Andre T(2015)Hypothesis: Obesity is associated with a lower mutation threshold in Colon Cancer Journal of Cancer. 6 825-1372